학술논문
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Document Type
Article
Author
Source
In eClinicalMedicine August 2023 62
Subject
Language
ISSN
2589-5370